4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Biotechnology

Healthcare
$10.46 +1.70%

+$0.16 today

Market cap
$577.85M
Beta
2.76
P/E (TTM)
-4.0
EPS (TTM)
-$2.36
52W Low $3.68High $12.34

Volume 0.68M

Average 0.77M

FDMT Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

4D Molecular Therapeutics, Inc.NASDAQ: FDMT

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 45.7% from a year ago

Cash & equivalents stood at $72.49M at the end of Q1 FY2026, down 45.7% from a year earlier and up 20.3% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.

Context

  • Cash & equivalents amounted to 14.1% of total assets at the end of Q1 FY2026, down 11.8 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -45.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$72.49M+20.3% QoQ
Last fiscal yearDec 2025
$60.24M-59.7% YoY
Year agoMar 2025
$133.53M-45.7% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-45.7%——
1 year-59.7%——
3-year CAGR+4.8%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
60.24M USD
Year-over-year change
-59.7%
4-year CAGR
-20.8%

Cash & Equivalents vs competitors

How FDMT compares with its peers on the latest reported figures

  • FDMT's Mar 2026 cash & equivalents of $72.49M is the 3rd highest of the 8 companies compared; the peer median is $71.54M.
  • Its year-over-year change of -45.7% is the 7th highest of 8, against a peer median of +7.5%.
  • Cash & equivalents amounts to 14.1% of total assets for FDMT, versus a peer median of 29.2%.
FDMT Competitors Peer median
Cash & Equivalents for FDMT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SLDBSolid Biosciences Inc.Mar 2026$297.74M +41.4%-27.2%70.4%
QUREuniQure N.V.Mar 2026$139.99M -35.6%-29.4%18.0%
FDMT4D Molecular Therapeutics, Inc.Mar 2026$72.49M -45.7%+4.8%14.1%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$71.77M +148.2%-6.6%28.7%
MGTXMeiraGTx Holdings plcMar 2026$71.54M +7.5%-17.1%29.2%
ABEOAbeona Therapeutics Inc.Mar 2026$61.37M +285.1%+76.7%30.9%
OCGNOcugen, Inc.Mar 2026$31.86M -15.7%-37.9%56.0%
RGNXREGENXBIO Inc.Mar 2026$15.23M -88.3%-29.2%4.5%
Peer median (excluding FDMT) $71.54M+7.5%-27.2%29.2%

Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents153M52.35M249.11M149.34M60.24M
Short-term Investments94.78M161.2M39.12M275.54M342.41M
Net Receivables47K700K000
Inventory00000
Other Current Assets8.46M6.26M8.36M10.06M10.48M
Total Current Assets256.28M220.51M296.59M434.93M413.13M
Property, Plant & Equipment (Net)28.95M35.35M31.67M40.61M33.01M
Goodwill00000
Intangible Assets00000
Long-term Investments67.65M4.91M10.95M80.58M111.38M
Tax Assets00000
Other Non-current Assets602K1.08M684K4.26M9.19M
Total Non-current Assets97.21M41.34M43.3M125.45M153.58M
Total Assets353.49M261.85M339.89M560.38M566.71M
Account Payables4.76M3.32M3.52M4.39M11.16M
Short-term Debt02.66M000
Tax Payables00000
Deferred Revenue2.6M884K273K257K360K
Other Current Liabilities03.18M3.87M00
Total Current Liabilities16.34M15.73M18.95M29.15M43.99M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)2.49M1.08M972K1.06M745K
Other Non-current Liabilities334K233K617K603K496K
Total Non-current Liabilities18.04M14.78M13.11M20.63M17.06M
Total Liabilities34.38M30.51M32.06M49.78M61.05M
Common Stock3K3K4K5K6K
Retained Earnings(207M)(314.49M)(415.33M)(576.2M)(716.3M)
Accumulated OCI(423K)(1.2M)16K229K727K
Other Stockholders Equity00000
Minority Interest00000
Total Equity319.11M231.34M307.83M510.61M505.66M
Total Debt16.45M16.12M14.67M24.61M21.41M
Net Debt(136.55M)(36.23M)(234.44M)(124.73M)(38.83M)

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Intrinsic Alpha fair value

Locked

Current Price

$10.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.